Evaluation of Patiromer Titration in Heart Failure Patients With Chronic Kidney Disease

Inclusion Criteria

• Chronic HF clinically indicated to receive spironolactone therapy
• Age 18 years or older
• Local laboratory serum potassium values of 4.3 - 5.1 mEq/L at screening and baseline
• CKD (estimated glomerular filtration rate [eGFR] 180 or 3 times upper limit of normal
• Loop and thiazide diuretics that have not been stable for at least 21 days prior to baseline or not anticipated to remain stable during study participation
• Use of any intravenous cardiac medications within 21 days prior to baseline, or their anticipated need during study participation
• Current use of polymer-based drugs (e.g., sevelamer, sodium polystyrene sulfonate, colesevelam, colestipol), phosphate binders (e.g., lanthanum carbonate), or other potassium binders, or their anticipated need during study participation
• Use of potassium sparing medication including aldosterone antagonists or potassium supplements in the last 21 days prior to baseline
• Use of any investigational medication within 30 days or 5 half-lives, whichever is longer, prior to baseline
• Participants who have taken investigational product in this study, or a previous patiromer study
• Inability to consume the study medication, or, in the opinion of the Investigator, inability to comply with the protocol
• In the opinion of the Investigator, any medical condition, uncontrolled systemic disease, serious intercurrent illness, or extenuating circumstance occurring or persisting, within 30 days prior to baseline, that would significantly decrease study compliance or jeopardize the safety of the participant or affect the validity of the trial results